18 rectal cancer patients were given dostarlimab every three weeks for six months and ended up cancer-free………………………….“I believe this is the first time this has happened in the history of cancer………”
‘Remarkable breakthrough’ in cancer research…
‘Unprecedented’, ‘Remarkable’: Cancer Study Leaves Every Patient Cancer-Free | The Daily Wire
Study Leaves Every Patient Cancer-Free
“I believe this is the first time this has happened in the history of cancer.”
Results from a small cancer trial that left every patient in remission is being praised as “unprecedented” and “remarkable.” A paper published on Sunday at The New England Journal of Medicine outlined a study of 18 rectal cancer patients who were given dostarlimab every three weeks for six months and ended up cancer-free, including the first patient who is now two years out from the trial.
“I believe this is the first time this has happened in the history of cancer,” said Dr. Luis A. Diaz Jr. said, an author of the paper, The New York Times reported. Dr. Andrea Cercek, an oncologist at Memorial Sloan Kettering Cancer Center and another author of the paper, described “a lot of happy tears” at the end of the trial.
While noting the study needs replication, Dr. Kimmie Ng, a colorectal cancer expert at Harvard Medical School, called the trial results “remarkable” and “unprecedented.”
“We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery.”
Those who took the drug, which “unmasks cancer cells, allowing the immune system to identify and destroy them,” did not have to move on to further cancer treatments.
“All the patients had a clinical complete response, with no evidence of tumor on magnetic resonance imaging,” the paper explained. “At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.”
